Autifony begins Phase Ib of AUT00206 in schizophrenia

Autifony Therapeutics Ltd. (Stevenage, U.K.) began a double-blind, placebo-controlled, U.K. Phase Ib trial of twice-daily 800 mg oral AUT00206 for 4 weeks as adjunctive therapy in about 24 recently d...